Following in the footsteps of acute myeloid leukemia: Are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?

For most patients with higher-risk myelodysplastic syndromes (HR-MDS) the hypomethylating agents (HMA) azacitidine and decitabine remain the mainstay of therapy. However, the prognosis mostly remains poor and aside from allogeneic hematopoietic stem cell transplantation no curative treatment options...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leuk Lymphoma
Hlavní autoři: Bewersdorf, Jan Philipp, Zeidan, Amer M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7670856/
https://ncbi.nlm.nih.gov/pubmed/32421403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1761968
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky